Acquired lipodystrophy

Last revised by Frank Gaillard on 22 May 2023

Acquired lipodystrophy is defined by the loss of body fat, insulin resistance and metabolic profile derangement. Subtypes include Barraquer-Simons syndrome, localized lipodystrophy and Lawrence syndromeLipodystrophy is illustrated as a complete or partial loss of adipose tissues from the body. 

Overactivation of the complement system has been documented in most cases of acquired lipodystrophy 4. The condition is often seen in patients on certain medications including older antiretroviral agents for HIV (see HIV-associated lipodystrophy) disease but may also be seen in some autoimmune diseases or be idiopathic.

Whole-body MR is the modality of preference to see the pattern of fat loss (and in some cases concurrent regional lipomatosis) in acquired lipodystrophy.

A multidisciplinary therapeutic strategy includes counseling, metreleptin (recombinant leptin) 6, symptomatic treatment and managing any underlying primary disease. 

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.